Mitochondrial dysfunction as a central event for mechanisms underlying insulin resistance: The roles of long chain fatty acids

Diabetes/Metabolism Research and Reviews

Volumn 31, Issue 5, 2015, Pages 453-475

  Hafizi Abu Bakar, Mohamad ^a   Kian Kai, Cheng ^a   Wan Hassan, Wan Najihah ^a   Sarmidi, Mohamad Roji ^a   Yaakob, Harisun ^a   Zaman Huri, Hasniza ^b,c  

^a UNIVERSITI TEKNOLOGI MALAYSIA   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Inflammation; Insulin resistance; Lipotoxicity; Long chain fatty acids; Mitochondrial dysfunction; Reactive oxygen species

Indexed keywords

INSULIN; LONG CHAIN FATTY ACID; REACTIVE OXYGEN METABOLITE; FATTY ACID;

DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM STRESS; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCOSE OXIDATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPOTOXICITY; MITOCHONDRIAL GENE; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DYSLIPIDEMIA; HYPERGLYCEMIA; METABOLISM; OXIDATIVE STRESS;

ANIMALS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FATTY ACIDS; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; MITOCHONDRIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84935098094     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2601     Document Type: Review

References (259)

1. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005; 36: 197-209.
2. Schäfer S A, Machicao F, Fritsche A, Häring H-U, Kantartzis K. New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms. Diabetes Res Clin Pract 2011; 93(Suppl 1): S9-24.
3. Barroso I. Genetics of type 2 diabetes. Diabet Med 2005; 22: 517-535.
4. Pierce M, Keen H, Bradley C. Risk of diabetes in offspring of parents with non-insulin-dependent diabetes. Diabet Med 1995; 12: 6-13.
5. Weires MB, Tausch B, Haug PJ, Edwards CQ, Wetter T, Cannon-Albright LA. Familiality of diabetes mellitus. Exp Clin Endocrinol Diabetes 2007; 115: 634-640.
6. Herman WH, Zimmet P. Type 2 diabetes: an epidemic requiring global attention and urgent action. Diabetes Care 2012; 35(5): 943-944.
7. Cornelis MC, Hu FB. Gene-environment interactions in the development of type 2 diabetes: recent progress and continuing challenges. Annu Rev Nutr 2012; 32: 245-259.
8. Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 2011; 18: 139-143.
9. Brody T. Nutritional Biochemistry. Academic Press: San Diego, California, 1999; 1006.
10. Lee JS, Pinnamaneni SK, Eo SJ, et al. Saturated, but not n-6 polyunsaturated, fatty acids induce insulin resistance: role of intramuscular accumulation of lipid metabolites. J Appl Physiol 2006; 100: 1467-1474.
11. Clément L, Poirier H, Niot I, et al. Dietary trans-10, cis-12 conjugated linoleic acid induces hyperinsulinemia and fatty liver in the mouse. J Lipid Res 2002; 43(9): 1400-1409.
12. Risérus U, Vessby B, Arner P, Zethelius B. Supplementation with trans10cis12-conjugated linoleic acid induces hyperproinsulinaemia in obese men: close association with impaired insulin sensitivity. Diabetologia 2004; 47: 1016-1019.
13. Clarke SD, Hembree J. Inhibition of triiodothyronine's induction of rat liver lipogenic enzymes by dietary fat. J Nutr 1990; 120(6): 625-630.
14. Yuzefovych L, Wilson G, Rachek L. Different effects of oleate vs. palmitate on mitochondrial function, apoptosis, and insulin signaling in L6 skeletal muscle cells: role of oxidative stress. Am J Physiol - Endocrinol Metab 2010; 299(6): E1096-E1105.
15. Hecker M, Sommer N, Voigtmann H, et al. Impact of short- and medium-chain fatty acids on mitochondrial function in severe inflammation. J Parenter Enter Nutr 2013; 38(5): 587-594.
16. Turner N, Hariharan K, TidAng J, et al. Enhancement of muscle mitochondrial oxidative capacity and alterations in insulin action are lipid species dependent: potent tissue-specific effects of medium-chain fatty acids. Diabetes 2009; 58(11): 2547-2554.
17. Patti M-E, Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 2010; 31: 364-95.
18. Pagel-Langenickel I, Bao J, Pang L, Sack MN. The role of mitochondria in the pathophysiology of skeletal muscle insulin resistance. Endocr Rev 2010; 31: 25-51.
19. Martin SD, McGee SL. The role of mitochondria in the aetiology of insulin resistance and type 2 diabetes. Biochim Biophys Acta 2013; 1840: 1303-1312.
20. Mogensen M, Sahlin K, Fernstro M, et al. Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes 2007; 56: 1592-1599.
21. Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci 2003; 100(14): 8466-8471.
22. Mootha VK, Lindgren CM, Eriksson K-F, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-273.
23. Szendroedi J, Schmid AI, Meyerspeer M, et al. Impaired mitochondrial function and insulin resistance of skeletal muscle in mitochondrial diabetes. Diabetes Care 2009; 32(4): 677-679.
24. Gao C-L, Zhu C, Zhao Y-P, et al. Mitochondrial dysfunction is induced by high levels of glucose and free fatty acids in 3T3-L1 adipocytes. Mol Cell Endocrinol 2010; 320: 25-33.
25. Hammarstedt A, Jansson P-A, Wesslau C, Yang X, Smith U. Reduced expression of PGC-1 and insulin-signaling molecules in adipose tissue is associated with insulin resistance. Biochem Biophys Res Commun 2003; 301: 578-582.
26. Nakamura S, Takamura T, Matsuzawa-Nagata N, et al. Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. J Biol Chem 2009; 284(22): 14809-14818.
27. Newsholme P, Gaudel C, Krause M. Mitochondria and diabetes. An intriguing pathogenetic role. In Adv Mitochondrial Med. Volume 942. Scatena R, Bottoni P, Giardina B (eds). Springer: Netherlands, 2012; 235-247. [Advances in Experimental Medicine and Biology]
28. Saini V. Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes 2010; 1: 68-75.
29. Kraegen EW, Cooney GJ. Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol 2008; 19: 235-241.
30. Abdul-Ghani M, DeFronzo R. Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus. Curr Diab Rep 2008; 8: 173-178.
31. Schrauwen P, Schrauwen-Hinderling V, Hoeks J, Hesselink MKC. Mitochondrial dysfunction and lipotoxicity. Biochim Biophys Acta 2010; 1801: 266-71.
32. Hoeks J, Schrauwen P. Muscle mitochondria and insulin resistance: a human perspective. Trends Endocrinol Metab 2014; 23: 444-450.
33. Pagliarini DJ, Calvo SE, Chang B, et al. A mitochondrial protein compendium elucidates complex I disease biology. Cell 2008; 134: 112-123.
34. Soria LR, Marrone J, Calamita G, Marinelli RA. Ammonia detoxification via ureagenesis in rat hepatocytes involves mitochondrial aquaporin-8 channels. Hepatology 2013; 57: 2061-2071.
35. Giorgi C, Agnoletto C, Bononi A, et al. Mitochondrial calcium homeostasis as potential target for mitochondrial medicine. Mitochondrion 2012; 12: 77-85.
36. Yoon Y, Galloway CA, Jhun BS, Yu T. Mitochondrial dynamics in diabetes. Antioxid Redox Signal 2011; 14: 439-457.
37. Nieminen A-L. Apoptosis and necrosis in health and disease: role of mitochondria. Int Rev Cytol 2003; 224: 29-55.
38. Maechler P, Wollheim CB. Mitochondrial function in normal and diabetic [beta]-cells. Nature 2001; 414: 807-812.
39. Amacher DE. Drug-associated mitochondrial toxicity and its detection. Curr Med Chem 2005; 12: 1829-1839.
40. De Souza-Pinto NC, Mason PA, Hashiguchi K, et al. Novel DNA mismatch-repair activity involving YB-1 in human mitochondria. DNA Repair (Amst) 2009; 8: 704-719.
41. Boelsterli UA, Lim PLK. Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharmacol 2007; 220: 92-107.
42. Desler C, Lykke A, Rasmussen LJ. The effect of mitochondrial dysfunction on cytosolic nucleotide metabolism. J Nucleic Acids 2010; 2010: 12725-12732.
43. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001; 104: 531-543.
44. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Sci 2005; 307(5708): 384-387.
45. Jing E, Emanuelli B, Hirschey MD, et al. Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production. In Proc Natl Acad Sci USA 2011; 108: 14608-14613.
46. Matsuzaki S, Szweda PA, Szweda LI, Humphries KM. Regulated production of free radicals by the mitochondrial electron transport chain: cardiac ischemic preconditioning. Adv Drug Deliv Rev 2009; 61: 1324-1331.
47. Newsholme P, Haber EP, Hirabara SM, et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol 2007; 583(1): 9-24.
48. Wei Y, Chen K, Whaley-Connell AT, Stump CS, Ibdah JA, Sowers JR. Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol - Regul Integr Comp Physiol 2008; 23: R673-R680.
49. Muoio DM, Neufer PD. Lipid-induced mitochondrial stress and insulin action in muscle. Cell Metab 2012; 15: 595-605.
50. Garland PB, Newsholme EA, Randle PJ. Effect of fatty acids, ketone bodies, diabetes and starvation on pyruvate metabolism in rat heart and diaphragm muscle. Nature 1962; 195: 507-520.
51. Newsholme EA, Randle PJ, Manchester KL. Inhibition of the phosphofructokinase reaction in perfused rat heart by respiration of ketone bodies, fatty acids and pyruvate. Nature 1962; 193: 270-271.
52. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle its role in insulin sensitivity and the metabolic disturbance of diabetes mellitus. Lancet 1963; 281: 785-789.
53. Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35years. Diabetes Metab Rev 1999; 14: 263-283.
54. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103: 253-259.
55. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999; 48: 1270-1274.
56. Oakes ND, Bell KS, Furler SM, et al. Diet-induced muscle insulin resistance in rats is ameliorated by acute dietary lipid withdrawal or a single bout of exercise: parallel relationship between insulin stimulation of glucose uptake and suppression of long-chain fatty acyl-CoA. Diabetes 1997; 46(12): 2022-2028.
57. Roden M. How free fatty acids inhibit glucose utilization in human skeletal muscle. Physiol 2004; 19(3): 92-96.
58. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97: 2859-2865.
59. Ma ZA, Zhao Z, Turk J. Mitochondrial dysfunction and β-cell failure in type 2 diabetes mellitus. Exp Diabetes Res 2012; 2012: 703538.
60. Katan MB, Zock PL, Mensink RP. Effects of fats and fatty acids on blood lipids in humans: an overview. Am J Clin Nutr 1994; 60(6): 1017S-1022S.
61. Gaster M, Rustan AC, Beck-Nielsen H. Differential utilization of saturated palmitate and unsaturated oleate: evidence from cultured myotubes. Diabetes 2005; 54(3): 648-656.
62. Vasudevan. Textbook of Biochemistry for Dental Students (5th edn). Jaypee Brothers, Medical Publishers, 2007; 1-314.
63. Cameron-Smith D, Burke LM, Angus DJ, et al. A short-term, high-fat diet up-regulates lipid metabolism and gene expression in human skeletal muscle. Am J Clin Nutr 2003; 77(2): 313-318.
64. Primeaux S, Braymer HD, Bray G. CD36 mRNA in the gastrointestinal tract is differentially regulated by dietary fat intake in obesity-prone and obesity-resistant rats. Dig Dis Sci 2013; 58: 363-370.
65. Coburn CT, Knapp FF, Febbraio M, Beets AL, Silverstein RL, Abumrad NA. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J Biol Chem 2000; 275(42): 32523-32529.
66. Zhang L, Keung W, Samokhvalov V, Wang W, Lopaschuk GD. Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle. Biochim Biophys Acta 2010; 1801(1): 1-22.
67. Ceccarelli SM, Chomienne O, Gubler M, Arduini A. Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35years of research. J Med Chem 2011; 54: 3109-3152.
68. Brownsey RW, Boone AN, Elliott JE, Kulpa JE, Lee WM. Regulation of acetyl-CoA carboxylase. Biochem Soc Trans 2006; 34(Pt 2): 223-227.
69. Kim J-Y, Hickner RC, Cortright RL, Dohm GL, Houmard JA. Lipid oxidation is reduced in obese human skeletal muscle. Am J Physiol - Endocrinol Metab 2000; 279(5): E1039-E1044.
70. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes 2006; 55(8): 2277-2285.
71. Adams SH, Hoppel CL, Lok KH, et al. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid β-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 2009; 139: 1073-1081.
72. Van Eunen K, Simons SM, Gerding A, et al. Biochemical competition makes fatty-acid β-oxidation vulnerable to substrate overload. PLoS Comput Biol 2013; 9: e1003186.
73. Koves TR, Ussher JR, Noland RC, et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008; 7: 45-56.
74. Möder M, Kießling A, Löster H, Brüggemann L. The pattern of urinary acylcarnitines determined by electrospray mass spectrometry: a new tool in the diagnosis of diabetes mellitus. Anal Bioanal Chem 2003; 375: 200-210.
75. Kim SC, Sprung R, Chen Y, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 2006; 23: 607-618.
76. Muoio DM, Koves TR. Skeletal muscle adaptation to fatty acid depends on coordinated actions of the PPARs and PGC1α: implications for metabolic disease. Appl Physiol Nutr Metab 2007; 32: 874-883.
77. Andreyev AY, Kushnareva YE, Starkov AA. Mitochondrial metabolism of reactive oxygen species. Biochem Biokhimii{combining double inverted breve}a 2005; 70: 200-14.
78. Laguens R, Bianchi N. Fine structure of the liver in human idiopathic diabetes mellitus: I. Parenchymal cell mitochondria. Exp Mol Pathol 1963; 2: 203-214.
79. Jucker BM, Dufour S, Ren J, et al. Assessment of mitochondrial energy coupling in vivo by 13C/31P NMR. Proc Natl Acad Sci 2000; 97(12): 6880-6884.
80. Petersen KF, Shulman GI, Petersen KF. GIS. Etiology of insulin resistance. Am J Med 2006; 119: S10-S16.
81. Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 92-103.
82. Galgani JE, Moro C, Ravussin E. Metabolic flexibility and insulin resistance. Am J Physiol - Endocrinol Metab 2008; 295: E1009-E1017.
83. Corpeleijn E, Saris WHM, Blaak EE. Metabolic flexibility in the development of insulin resistance and type 2 diabetes: effects of lifestyle. Obes Rev 2009; 10: 178-193.
84. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846.
85. Choi K, Kim YB. Molecular mechanism of insulin resistance in obesity and type 2 diabetes. Korean J Intern Med 2010; 25: 119-129.
86. Estadella D, da Penha Oller do Nascimento CM, Oyama LM, Ribeiro EB, Dâmaso AR, de Piano A. Lipotoxicity: effects of dietary saturated and transfatty acids. Mediators Inflamm 2013; 2013: 137579.
87. Eckel RH, Kahn SE, Ferrannini E, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care 2011; 34(6): 1424-1430.
88. Jocken JE, Goossens G, Boon H, et al. Insulin-mediated suppression of lipolysis in adipose tissue and skeletal muscle of obese type 2 diabetic men and men with normal glucose tolerance. Diabetologia 2013; 56: 2255-2265.
89. Friedrich N. Metabolomics in diabetes research. J Endocrinol 2012; 0049: 1-33.
90. Henriksen EJ, Diamond-Stanic MK, Marchionne EM. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic Biol Med 2011; 51: 993-999.
91. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107(9): 1058-1070.
92. Brodská B, Holoubek A. Generation of reactive oxygen species during apoptosis induced by DNA-damaging agents and/or histone deacetylase inhibitors. Oxid Med Cell Longev 2011; 2011: 253529.
93. Indo HP, Davidson M, Yen H-C, et al. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion 2007; 7: 106-118.
94. Schönfeld P, Wojtczak L. Fatty acids decrease mitochondrial generation of reactive oxygen species at the reverse electron transport but increase it at the forward transport. Biochim Biophys Acta 2007; 1767: 1032-1040.
95. Barja G. Mitochondrial oxygen radical generation and leak: sites of production in states 4 and 3, organ specificity, and relation to aging and longevity. J Bioenerg Biomembr 1999; 31: 347-366.
96. Johannsen DL, Ravussin E. The role of mitochondria in health and disease. Curr Opin Pharmacol 2009; 9: 780-786.
97. Warburton DER, Nicol CW, Bredin SSD. Health benefits of physical activity: the evidence. Can Med Assoc J 2006; 174(6): 801-809.
98. Santos CX, Tanaka LY, Wosniak J, Laurindo FR. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal 2009; 11: 2409-2427.
99. Stone JR, Yang S. Hydrogen peroxide: a signaling messenger. Antioxid Redox Signal 2006; 8: 243-270.
100. Brand MD. The sites and topology of mitochondrial superoxide production. Exp Gerontol 2010; 45: 466-472.
101. Mensink M, Blaak EE, van Baak MA, Wagenmakers AJM, Saris WHM. Plasma free fatty acid uptake and oxidation are already diminished in subjects at high risk for developing type 2 diabetes. Diabetes 2001; 50(11): 2548-2554.
102. Soardo G, Donnini D, Domenis L, et al. Oxidative stress is activated by free fatty acids in cultured human hepatocytes. Metab Syndr Relat Disord 2011; 9: 397-401.
103. Song JH, Fujimoto K, Miyazawa T. Polyunsaturated (n-3) fatty acids susceptible to peroxidation are increased in plasma and tissue lipids of rats fed docosahexaenoic acid-containing oils. J Nutr 2000; 130(12): 3028-3033.
104. Duval C, Cámara Y, Hondares E, Sibille B, Villarroya F. Overexpression of mitochondrial uncoupling protein-3 does not decrease production of the reactive oxygen species, elevated by palmitate in skeletal muscle cells. FEBS Lett 2007; 581: 955-961.
105. Lambertucci RH, Hirabara SM, Silveira Ldos R, Levada-Pires AC, Curi R, Pithon-Curi TC. Palmitate increases superoxide production through mitochondrial electron transport chain and NADPH oxidase activity in skeletal muscle cells. J Cell Physiol 2008; 216: 955-961.
106. Kim J, Minkler PE, Salomon RG, Anderson VE, Hoppel CL. Cardiolipin: characterization of distinct oxidized molecular species. J Lipid Res 2011; 52(1): 125-135.
107. Meex RCR, Schrauwen-hinderling VB, Moonen-kornips E, et al. Restoration of muscle mitochondrial function and metabolic flexibility in type 2 diabetes by exercise training is paralleled by increased myocellular fat storage and improved insulin sensitivity. Diabetes 2010; 59(3): 572-579.
108. Bandeira SM, Guedes GS, da Fonseca LJ, et al. Characterization of blood oxidative stress in type 2 diabetes mellitus patients: increase in lipid peroxidation and SOD activity. Oxid Med Cell Longev 2012; 2012: 819310.
109. Garcia J, Han D, Sancheti H, Yap LP, Kaplowitz N, Cadenas E. Regulation of mitochondrial glutathione redox status and protein glutathionylation by respiratory substrates. J Biol Chem 2010; 285: 39646-39654.
110. 2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 2009; 119: 573-581.
111. 2 emission without affecting respiratory capacity in skeletal muscle of obese rats. Free Radic Biol Med 2010; 49: 1082-1087.
112. Borradaile NM, Buhman KK, Listenberger LL, et al. A critical role for eukaryotic elongation factor 1A-1 in lipotoxic cell death. Mol Biol Cell 2006; 17(2): 770-778.
113. Cacicedo JM, Benjachareowong S, Chou E, Ruderman NB, Ido Y. Palmitate-induced apoptosis in cultured bovine retinal pericytes: roles of NAD(P)H oxidase, oxidant stress, and ceramide. Diabetes 2005; 54(6): 1838-1845.
114. Den Hartigh LJ, Han CY, Wang S, Omer M, Chait A. 10E, 12Z-conjugated linoleic acid impairs adipocyte triglyceride storage by enhancing fatty acid oxidation, lipolysis, and mitochondrial reactive oxygen species. J Lipid Res 2013; 54: 2964-2978.
115. Zarrouk A, Vejux A, Nury T, et al. Induction of mitochondrial changes associated with oxidative stress on very long chain fatty acids (C22:0, C24:0, or C26:0)-treated human neuronal cells (SK-NB-E). Oxid Med Cell Longev 2012; 2012: 623257.
116. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002; 51: 2944-50.
117. Heilbronn LK, Gan SK, Turner N, Campbell LV, Chisholm DJ. Markers of mitochondrial biogenesis and metabolism are lower in overweight and obese insulin-resistant subjects. J Clin Endocrinol Metab 2007; 92(4): 1467-1473.
118. Vankoningsloo S, Piens M, Lecocq C, et al. Mitochondrial dysfunction induces triglyceride accumulation in 3T3-L1 cells: role of fatty acid β-oxidation and glucose. J Lipid Res 2005; 46(6): 1133-1149.
119. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761.
120. Paglialunga S, Bree B, Bosma M, et al. Targeting of mitochondrial reactive oxygen species production does not avert lipid-induced insulin resistance in muscle tissue from mice. Diabetologia 2012; 55: 2759-2768.
121. De Feyter HM, van den Broek NMA, Praet SFE, Nicolay K, van Loon LJC, Prompers JJ. Early or advanced stage type 2 diabetes is not accompanied by in vivo skeletal muscle mitochondrial dysfunction. Eur J Endocrinol 2008; 158(5): 643-653.
122. Barroso I, Luan J, Sandhu MS, et al. Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia 2006; 49: 501-505.
123. Ling C, Poulsen P, Simonsson S, et al. Genetic and epigenetic factors are associated with expression of respiratory chain component NDUFB6 in human skeletal muscle. J Clin Invest 2007; 117: 3427-3435.
124. Nakanishi S, Yamane K, Ohishi W, et al. Manganese superoxide dismutase Ala16Val polymorphism is associated with the development of type 2 diabetes in Japanese-Americans. Diabetes Res Clin Pract 2008; 81: 381-385.
125. Park KS, Chan JC, Chuang L-M, et al. A mitochondrial DNA variant at position 16189 is associated with type 2 diabetes mellitus in Asians. Diabetologia 2008; 51: 602-608.
126. Guo L-J, Oshida Y, Fuku N, et al. Mitochondrial genome polymorphisms associated with type-2 diabetes or obesity. Mitochondrion 2005; 5: 15-33.
127. Shenouda SM, Widlansky ME, Chen K, et al. Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. Circulation 2011; 124: 444-453.
128. Seo AY, Joseph A-M, Dutta D, Hwang JCY, Aris JP, Leeuwenburgh C. New insights into the role of mitochondria in aging: mitochondrial dynamics and more. J Cell Sci 2010; 123(15): 2533-2542.
129. Joseph AM, Joanisse DR, Baillot RG, Hood DA. Mitochondrial dysregulation in the pathogenesis of diabetes: potential for mitochondrial biogenesis-mediated interventions. Exp Diabetes Res 2012; 2012: 642038.
130. Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev 2008; 88: 611-638.
131. Arany Z. PGC-1 coactivators and skeletal muscle adaptations in health and disease. Curr Opin Genet Dev 2008; 18: 426-434.
132. Evans RM, Barish GD, Wang Y-X. PPARs and the complex journey to obesity. Nat Med 2004; 10: 355-361.
133. Diradourian C, Girard J, Pégorier J-P. Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 2005; 87: 33-38.
134. Zhang J, Phillips DIW, Wang C, Byrne CD. Human skeletal muscle PPARα expression correlates with fat metabolism gene expression but not BMI or insulin sensitivity. Am J Physiol - Endocrinol Metab 2004; 286(2): E168-E175.
135. Song S, Attia RR, Connaughton S, et al. Peroxisome proliferator activated receptor α (PPARα) and PPAR gamma coactivator (PGC-1α) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements. Mol Cell Endocrinol 2010; 325: 54-63.
136. Coll T, Jové M, Rodríguez-Calvo R, et al. Palmitate-mediated downregulation of peroxisome proliferator-activated receptor-γ coactivator 1α in skeletal muscle cells involves MEK1/2 and nuclear factor-κB activation. Diabetes 2006; 55: 2779-2787.
137. Pimenta AS, Gaidhu MP, Habib S, et al. Prolonged exposure to palmitate impairs fatty acid oxidation despite activation of AMP-activated protein kinase in skeletal muscle cells. J Cell Physiol 2008; 217: 478-485.
138. Sparks LM, Xie H, Koza RA, et al. A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle. Diabetes 2005; 54(7): 1926-1933.
139. Hoeks J, Hesselink MKC, Russell AP, et al. Peroxisome proliferator-activated receptor-γ coactivator-1 and insulin resistance: acute effect of fatty acids. Diabetologia 2006; 49: 2419-2426.
140. Jové M, Salla J, Planavila A, et al. Impaired expression of NADH dehydrogenase subunit 1 and PPARγ coactivator-1 in skeletal muscle of ZDF rats: restoration by troglitazone. J Lipid Res 2004; 45(1): 113-123.
141. Kleiner S, Mepani RJ, Laznik D, et al. Development of insulin resistance in mice lacking PGC-1α in adipose tissues. Proc Natl Acad Sci 2012; 109(24): 9635-9640.
142. Arany Z, Lebrasseur N, Morris C, et al. The transcriptional coactivator PGC-1 drives the formation of oxidative type IIX fibers in skeletal muscle. Cell Metab 2007; 5: 35-46.
143. Kim J-A, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res 2008; 102: 401-14.
144. Oikari S, Ahtialansaari T, Huotari A, et al. Effect of medium- and long-chain fatty acid diets on PPAR and SREBP-1 expression and glucose homeostasis in ACBP-overexpressing transgenic rats. Acta Physiol 2008; 194: 57-65.
145. Holloway GP, Perry CGR, Thrush AB, et al. PGC-1alpha's relationship with skeletal muscle palmitate oxidation is not present with obesity despite maintained PGC-1alpha and PGC-1beta protein. Am J Physiol Endocrinol Metab 2008; 294: E1060-E1069.
146. Bach D, Pich S, Soriano FX, et al. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism: a novel regulatory mechanism altered in obesity. J Biol Chem 2003; 278: 17190-17197.
147. Sebastián D, Hernández-Alvarez MI, Segalés J, et al. Mitofusin 2 (Mfn2) links mitochondrial and endoplasmic reticulum function with insulin signaling and is essential for normal glucose homeostasis. Proc Natl Acad Sci 2012; 109(14): 5523-5528.
148. Kong D, Song G, Wang C, et al. Overexpression of mitofusin 2 improves translocation of glucose transporter 4 in skeletal muscle of high-fat diet-fed rats through AMP-activated protein kinase signaling. Mol Med Rep 2013; 8: 205-210.
149. Gan KX, Wang C, Chen JH, Zhu CJ, Song GY. Mitofusin-2 ameliorates high-fat diet-induced insulin resistance in liver of rats. World J Gastroenterol 2013; 19: 1572-1581.
150. Gutierrez D, Puglisi M, Hasty A. Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia. Curr Diab Rep 2009; 9: 26-32.
151. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97.
152. Kennedy A, Martinez K, Chuang C-C, LaPoint K, McIntosh M. Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: mechanisms of action and implications. J Nutr 2009; 139(1): 1-4.
153. Gustafson B, Gogg S, Hedjazifar S, Jenndahl L, Hammarstedt A, Smith U. Inflammation and impaired adipogenesis in hypertrophic obesity in man. Am J Physiol - Endocrinol Metab 2009; 297: E999-E1003.
154. Tourniaire F, Romier-Crouzet B, Lee JH, et al. Chemokine expression in inflamed adipose tissue is mainly mediated by NF-κB. PLoS One 2013; 8: e66515.
155. Xu L, Spinas GA, Niessen M. ER stress in adipocytes inhibits insulin signaling, represses lipolysis, and alters the secretion of adipokines without inhibiting glucose transport. Horm Metab Res 2010; 42: 643-651.
156. Szendroedi J, Frossard M, Klein N, et al. Lipid-induced insulin resistance is not mediated by impaired transcapillary transport of insulin and glucose in humans. Diabetes 2012; 61(12): 3176-3180.
157. Consitt LA, Bell JA, Houmard JA. Intramuscular lipid metabolism, insulin action, and obesity. IUBMB Life 2009; 61: 47-55.
158. Samuel VT. Fructose induced lipogenesis: from sugar to fat to insulin resistance. Trends Endocrinol Metab 2011; 22: 60-65.
159. Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta - Mol Cell Biol Lipids 2010; 1801: 209-214.
160. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010; 53: 1270-1287.
161. Adams JM, Pratipanawatr T, Berria R, et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004; 53(1): 25-31.
162. De Vogel-van den Bosch J, Hoeks J, Timmers S, et al. The effects of long- or medium-chain fat diets on glucose tolerance and myocellular content of lipid intermediates in rats. Obesity 2011; 19: 792-799.
163. De Vogel-van den Bosch J, van den Berg SAA, Bijland S, et al. High-fat diets rich in medium- versus long-chain fatty acids induce distinct patterns of tissue specific insulin resistance. J Nutr Biochem 2011; 22: 366-371.
164. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010; 375: 2267-2277.
165. Nagle CA, Klett EL, Coleman RA. Hepatic triacylglycerol accumulation and insulin resistance. J Lipid Res 2009; 50(Supplement): S74-S79.
166. Zhang D, Liu Z-X, Choi CS, et al. Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. Proc Natl Acad Sci 2007; 104(43): 17075-17080.
167. Timmers S, Schrauwen P, de Vogel J. Muscular diacylglycerol metabolism and insulin resistance. Physiol Behav 2008; 94: 242-251.
168. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes 2002; 51(7): 2005-2011.
169. Galadari S, Rahman A, Pallichankandy S, Galadari A, Thayyullathil F. Role of ceramide in diabetes mellitus: evidence and mechanisms. Lipids Health Dis 2013; 12: 98.
170. Haimovitz-Friedman A, Kolesnick RN, Fuks Z. Ceramide signaling in apoptosis. Br Med Bull 1997; 53(3): 539-553.
171. Górski J. Ceramide and insulin resistance: how should the issue be approached? Diabetes 2012; 61(12): 3081-3083.
172. Straczkowski M, Kowalska I, Baranowski M, et al. Increased skeletal muscle ceramide level in men at risk of developing type 2 diabetes. Diabetologia 2007; 50: 2366-2373.
173. Di Paola M, Cocco T, Lorusso M. Ceramide interaction with the respiratory chain of heart mitochondria†. Biochemistry 2000; 39: 6660-6668.
174. Gudz TI, Tserng K-Y, Hoppel CL. Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J Biol Chem 1997; 272(39): 24154-24158.
175. Melissa ES, Trevor ST, Eric SB, et al. Mitochondrial fission mediates ceramide-induced metabolic disruption in skeletal muscle. Biochem J 2013; 456: 427-439.
176. Novgorodov SA, Wu BX, Gudz TI, et al. Novel pathway of ceramide production in mitochondria: thioesterase and neutral ceramidase produce ceramide from sphingosine and acyl-CoA. J Biol Chem 2011; 286(28): 25352-25362.
177. Coen PM, Hames KC, Leachman EM, et al. Reduced skeletal muscle oxidative capacity and elevated ceramide but not diacylglycerol content in severe obesity. Obesity 2013; 21: 2362-2371.
178. Straczkowski M, Kowalska I, Nikolajuk A, et al. Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. Diabetes 2004; 53(5): 1215-1221.
179. Hannun YA, Obeid LM. The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 2002; 277(29): 25847-25850.
180. Merrill AH Jr, Jones DD. An update of the enzymology and regulation of sphingomyelin metabolism. Biochim Biophys Acta - Lipids Lipid Metab 1990; 1044: 1-12.
181. Pickersgill L, Litherland GJ, Greenberg AS, Walker M, Yeaman SJ. Key role for ceramides in mediating insulin resistance in human muscle cells. J Biol Chem 2007; 282(17): 12583-12589.
182. Pinnamaneni SK, Southgate RJ, Febbraio MA, Watt MJ. Stearoyl CoA desaturase 1 is elevated in obesity but protects against fatty acid-induced skeletal muscle insulin resistance in vitro. Diabetologia 2006; 49: 3027-3037.
183. Holland WL, Brozinick JT, Wang L-P, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007; 5: 167-179.
184. Ussher JR, Koves TR, Cadete VJJ, et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 2010; 59(1): 2453-2464.
185. Thrush AB, Chabowski A, Heigenhauser GJ, McBride BW, Or-Rashid M, Dyck DJ. Conjugated linoleic acid increases skeletal muscle ceramide content and decreases insulin sensitivity in overweight, non-diabetic humans. Appl Physiol Nutr Metab 2007; 32: 372-382.
186. Yu C, Chen Y, Cline GW, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277(52): 50230-50236.
187. Erion DM, Shulman GI. Diacylglycerol-mediated insulin resistance. Nat Med 2010; 16: 400-402.
188. Zhang L, Ussher JR, Oka T, Cadete VJJ, Wagg C, Lopaschuk GD. Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc Res 2011; 89(1): 148-156.
189. Todd MK, Watt MJ, Le J, Hevener AL, Turcotte LP. Thiazolidinediones enhance skeletal muscle triacylglycerol synthesis while protecting against fatty acid-induced inflammation and insulin resistance. Am J Physiol - Endocrinol Metab 2007; 292: E485-E493.
190. Holden NS, Squires PE, Kaur M, Bland R, Jones CE, Newton R. Phorbol ester-stimulated NF-κB-dependent transcription: roles for isoforms of novel protein kinase C. Cell Signal 2008; 20: 1338-1348.
191. Lee DF, Kuo HP, Chen CT, et al. IKKbeta suppression of TSC1 function links the mTOR pathway with insulin resistance. Int J Mol Med 2008; 22: 633-638.
192. Zhang J, Gao Z, Yin J, Quon MJ, Ye J. S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-α signaling through IKK2. J Biol Chem 2008; 283(51): 35375-35382.
193. Bunn RC, Cockrell GE, Ou Y, Thrailkill KM, Lumpkin CK, Fowlkes JL. Palmitate and insulin synergistically induce IL-6 expression in human monocytes. Cardiovasc Diabetol 2010; 9: 73.
194. Emanuela F, Grazia M, de Marco R, Maria Paola L, Giorgio F, Marco B. Inflammation as a link between obesity and metabolic syndrome. J Nutr Metab 2012; 2012: 476380.
195. Holland WL, Bikman BT, Wang L-P, et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest 2011; 121: 1858-1870.
196. Hotamisligil GS. Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int J Obes (Lond) 2008; 32(Suppl 7): S52-4.
197. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
198. Arkan MC, Hevener AL, Greten FR, et al. IKK-[beta] links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191-198.
199. Reyna SM, Ghosh S, Tantiwong P, et al. Elevated Toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes 2008; 57: 2595-2602.
200. Frisard MI, McMillan RP, Marchand J, et al. Toll-like receptor 4 modulates skeletal muscle substrate metabolism. Am J Physiol - Endocrinol Metab 2010; 298: E988-E998.
201. Barton GM, Medzhitov R. Toll-like receptor signaling pathways the signal to move: D. discoideum go orienteering. Science (80-) 2003; 300(6): 1524-1525.
202. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17(1): 1-14.
203. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through toll-like receptor 4. J Biol Chem 2001; 276(20): 16683-16689.
204. Frost RA, Nystrom G, Burrows PV, Lang CH. Temporal differences in the ability of ethanol to modulate endotoxin-induced increases in inflammatory cytokines in muscle under in vivo conditions. Alcohol Clin Exp Res 2005; 29: 1247-1256.
205. Frost RA, Nystrom GJ, Lang CH. Multiple Toll-like receptor ligands induce an IL-6 transcriptional response in skeletal myocytes. Am J Physiol - Regul Integr Comp Physiol 2006; 290: 773-784.
206. Chavez JA, Summers SA. A ceramide-centric view of insulin resistance. Cell Metab 2012; 15: 585-594.
207. Davis JE, Gabler NK, Walker-Daniels J, Spurlock ME. Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity 2008; 16: 1248-1255.
208. Poggi M, Bastelica D, Gual P, et al. C3H/HeJ mice carrying a Toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 2007; 50: 1267-1276.
209. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 3015-3025.
210. Radin MS, Sinha S, Bhatt BA, Dedousis N, O'Doherty RM. Inhibition or deletion of the lipopolysaccharide receptor Toll-like receptor-4 confers partial protection against lipid-induced insulin resistance in rodent skeletal muscle. Diabetologia 2008; 51: 336-346.
211. Tsukumo DML, Carvalho-Filho MA, Carvalheira JBC, et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007; 56: 1986-1998.
212. Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 2007; 21(12): 1443-1455.
213. Abedini A, Shoelson SE. Inflammation and obesity: STAMPing out insulin resistance? Immunol Cell Biol 2007; 85: 399-400.
214. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
215. Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812-817.
216. Ji C, Chen X, Gao C, et al. IL-6 induces lipolysis and mitochondrial dysfunction, but does not affect insulin-mediated glucose transport in 3T3-L1 adipocytes. J Bioenerg Biomembr 2011; 43: 367-375 LA - English.
217. Jové M, Planavila A, Sánchez RM, Merlos M, Laguna JC, Vázquez-Carrera M. Palmitate induces tumor necrosis factor-α expression in C2C12 skeletal muscle cells by a mechanism involving protein kinase c and nuclear factor-κB activation. Endocrinol 2006; 147(1): 552-561.
218. Coletta DK, Mandarino LJ. Mitochondrial dysfunction and insulin resistance from the outside in: extracellular matrix, the cytoskeleton, and mitochondria. Am J Physiol - Endocrinol Metab 2011; 301(5): E749-E755.
219. Vaamonde-García C, Valcarcel-Ares N, Riveiro-Naveira R, Lema B, Blanco FJ, López-Armada MJ. Inflammatory response is modulated by mitochondrial dysfunction in cultured normal human chondrocytes. Ann Rheum Dis 2010; 69(Suppl 2): A15-A16.
220. Håversen L, Danielsson KN, Fogelstrand L, Wiklund O. Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages. Atherosclerosis 2009; 202: 382-393.
221. Garg AD, Kaczmarek A, Krysko O, Vandenabeele P, Krysko DV, Agostinis P. ER stress-induced inflammation: does it aid or impede disease progression? Trends Mol Med 2012; 18: 589-598.
222. Hummasti S, Hotamisligil GS. Endoplasmic reticulum stress and inflammation in obesity and diabetes. Circ Res 2010; 107(5): 579-591.
223. Boden G. Endoplasmic reticulum stress: another link between obesity and insulin resistance/inflammation? Diabetes 2009; 58(3): 518-519.
224. Leem J, Koh EH. Interaction between mitochondria and the endoplasmic reticulum: implications for the pathogenesis of type 2 diabetes mellitus. Exp Diabetes Res 2012; 2012: 242984.
225. Gregor MF, Hotamisligil GS. Thematic review series: adipocyte biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res 2007; 48(9): 1905-1914.
226. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010; 140: 900-917.
227. Diakogiannaki E, Morgan NG. Differential regulation of the ER stress response by long-chain fatty acids in the pancreatic beta-cell. Biochem Soc Trans 2008; 36(Pt 5): 959-962.
228. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-461.
229. Tuncman G, Hirosumi J, Solinas G, Chang L, Karin M, Hotamisligil GS. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci 2006; 103(28): 10741-10746.
230. Vallerie SN, Furuhashi M, Fucho R, Hotamisligil GS. A predominant role for parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity. PLoS One 2008; 3: e3151.
231. Salvadó L, Coll T, Gómez-Foix AM, et al. Oleate prevents saturated-fatty-acid-induced ER stress, inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism. Diabetologia 2013; 56: 1372-1382.
232. Yuzefovych LV, Musiyenko SI, Wilson GL, Rachek LI. Mitochondrial DNA damage and dysfunction, and oxidative stress are associated with endoplasmic reticulum stress, protein degradation and apoptosis in high fat diet-induced insulin resistance mice. PLoS One 2013; 8: e54059.
233. Corbould A, Kim YB, Youngren JF, et al. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 2005; 288: E1047-54.
234. Moura Neto A, Parisi MCR, Tambascia MA, Pavin EJ, Alegre SM, Zantut-Wittmann DE. Relationship of thyroid hormone levels and cardiovascular events in patients with type 2 diabetes. Endocrine 2013: 1-8.
235. Brown JE. Dysregulated adipokines in the pathogenesis of type 2 diabetes and vascular disease. Br J Diabetes Vasc Dis 2012; 12(5): 249-254.
236. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85-96.
237. Cohen P. The twentieth century struggle to decipher insulin signalling. Nat Rev Mol Cell Biol 2006; 7: 867-873.
238. Stump CS, Short KR, Bigelow ML, Schimke JM, Nair KS. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc Natl Acad Sci U S A 2003; 100: 7996-8001.
239. Boirie Y, Short KR, Ahlman B, Charlton M, Nair KS. Tissue-specific regulation of mitochondrial and cytoplasmic protein synthesis rates by insulin. Diabetes 2001; 50(12): 2652-2658.
240. Huang X, Eriksson KF, Vaag A, et al. Insulin-regulated mitochondrial gene expression is associated with glucose flux in human skeletal muscle. Diabetes 1999; 48: 1508-14.
241. Halvatsiotis PG, Turk D, Alzaid A, Dinneen S, Rizza RA, Nair KS. Insulin effect on leucine kinetics in type 2 diabetes mellitus. Diabetes Nutr Metab 2002; 15: 136-142.
242. Petersen KF, Dufour S, Shulman GI. Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med 2005; 2: e233.
243. Lanza IR, Sreekumaran Nair K. Regulation of skeletal muscle mitochondrial function: genes to proteins. Acta Physiol 2010; 199: 529-547.
244. Hirabara SM, Curi R, Maechler P. Saturated fatty acid-induced insulin resistance is associated with mitochondrial dysfunction in skeletal muscle cells. J Cell Physiol 2010; 222: 187-194.
245. Hawley JA, Burke LM, Angus DJ, Fallon KE, Martin DT, Febbraio MA. Effect of altering substrate availability on metabolism and performance during intense exercise. Br J Nutr 2000; 84: 829-838.
246. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007; 87: 507-520.
247. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 2000; 49(5): 677-683.
248. Koonen DPY, Glatz JFC, Bonen A, Luiken JJFP. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim Biophys Acta - Mol Cell Biol Lipids 2005; 1736: 163-180.
249. Watt MJ, Steinberg GR, Chen Z-P, Kemp BE, Febbraio MA. Fatty acids stimulate AMP-activated protein kinase and enhance fatty acid oxidation in L6 myotubes. J Physiol 2006; 574(1): 139-147.
250. Glatz JFC, Luiken JJFP, Bonen A. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Physiol Rev 2010; 90: 367-417.
251. Cooney GJ, Lyons RJ, Crew AJ, et al. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. EMBO J 2004; 23: 582-593.
252. Chavez JA, Summers SA. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys 2003; 419: 101-109.
253. Schmitz-peiffer C, Craig DL, Biden TJ. Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem 1999; 274: 24202-24210.
254. Chavez JA, Summers SA. Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms. Biochim Biophys Acta - Mol Cell Biol Lipids 2010; 1801: 252-265.
255. Schrauwen P, Hesselink MKC. Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes 2004; 53(6): 1412-1417.
256. Möhlig M, Isken F, Ristow M. Impaired mitochondrial activity and insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664-671.
257. Phielix E, Schrauwen-Hinderling VB, Mensink M, et al. Lower intrinsic ADP-stimulated mitochondrial respiration underlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic patients. Diabetes 2008; 57: 2943-2949.
258. Yuzefovych LV, Solodushko VA, Wilson GL, Rachek LI. Protection from palmitate-induced mitochondrial DNA damage prevents from mitochondrial oxidative stress, mitochondrial dysfunction, apoptosis, and impaired insulin signaling in rat L6 skeletal muscle cells. Endocrinol 2012; 153(1): 92-100.
259. Wang C-H, Wang C-C, Wei Y-H. Mitochondrial dysfunction in insulin insensitivity: implication of mitochondrial role in type 2 diabetes. Ann N Y Acad Sci 2010; 1201: 157-65.